Professor Shannon Westin is principal investigator of the DUO-E trial, here she speaks to DDW’s Megan Thomas about why the standard of care needs improving and the impact of therapeutic antibodies such as durvalumab. The DUO-E trial is a three-arm, randomised, double-blind, placebo-controlled, multicentre Phase III trial assessing the combination of durvalumab with platinum-based chemotherapy […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!